GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Parsaclisib overview

Parsaclisib is under development for the treatment of indolent/aggressive B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, hairy cell leukemia, Waldenstrom macroglobulinemia, Hodgkin's lymphoma, follicular lymphoma, relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma, salivary gland cancer, marginal zone lymphoma including extranodal, nodal, and splenic subtypes, newly diagnosed triple negative breast cancer, and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and autoimmune hemolytic anemia. It is a small molecule administered orally in the form of tablet. It acts by targeting phosphoinositide 3-kinase delta (PI3Kdelta).

The therapeutic candidate was also under development for HER2-positive breast cancer, endometrial cancer, gastric cancer, small cell lung cancer, triple negative breast cancer, ureter cancer, bladder, urethral cancer, head and neck cancer squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, triple-negative breast cancer, transitional cell carcinoma, pemphigus vulgaris and Sjogren's syndrome. It was under development for the treatment of relapsed and refractory diffuse large B-cell lymphoma, peripheral t-cell lymphoma, including peripheral t-cell lymphoma, unspecified type, anaplastic large cell lymphoma (ALK negative or positive), angioimmunoblastic T-cell lymphoma, enteropathy related T-cell lymphoma, hepatosplenic T-cell lymphoma, γ/δ T-cell lymphoma, NK/T-cell lymphoma.

Incyte overview

Incyte is a biopharmaceutical company, that discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

For a complete picture of Parsaclisib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.